Catalyst Wire Dossier Catalyst Wire Dossier

Arlocabtagene Autoleucel

BMS-986393 · Bristol Myers Squibb
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Arlocabtagene Autoleucel, covering 2026-02-10 to 2026-02-18. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

See pricing